Lamivudine Stavudine & Nevirapine

Lamivudine Stavudine & Nevirapine

Form: Tablet

Strength: Lamivudine 150 mg + Stavudine 30 or 40 mg + Nevirapine 200 mg

Reference Brands: Triomune®(Global)

Category: Anti Viral

Lamivudine, Stavudine & Nevirapine Tablets are a fixed-dose antiretroviral combination widely used in the management of HIV-1 infection, particularly in first-line ART regimens in developing countries. Available in strengths like 150/30/200 mg, this combination ensures improved patient compliance and cost-effective therapy. Marketed under trusted names like Triomune®, the formulation is procured by governments, NGOs, and hospitals across Africa, Asia, and Latin America. Through PharmaB2B platforms, buyers can access high-quality, WHO-GMP-compliant products in bulk for tenders, institutional supply, and public health programs. It remains a vital component in scaling up global HIV treatment access.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Zanamivir

Strength: 5 mg/blister

Form: Inhalation powder

Reference Brands: Relenza(EU & US)

View Details Get Enquiry
Oseltamivir Phosphate Capsule

Strength: Capsule- 30 mg, 45 mg, 75 mg; Oral Suspension - 6 mg/mL (reconstituted)

Form: Capsules and Oral solution

Reference Brands: Tamiflu(EU & US)

View Details Get Enquiry
Amantadine

Strength: Tab -100 mg; Capsule- 100 mg; Oral solution - 50 mg/5 mL; Extended-release capsule (ER) - 129 mg, 193 mg

Form: Tablet; Capsule; Oral Solution and ER Capsule

Reference Brands: Symmetrel(EU & US); Osmolex ER(US), Gocovri(US)

View Details Get Enquiry
Glecaprevir + Pibrentasvir

Strength: Glecaprevir- 100 mg + Pibrentasvir - 40 mg

Form: Tablet

Reference Brands: Mavyret (US); Maviret (EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.